How many insider trades does FilingIQ track for MAIA?

FilingIQ tracks 168 Form 4 insider transactions for MAIA (MAIA Biotechnology, Inc.), covering filings from Jul 28, 2022 onwards. 9 of those were filed in the last 90 days.

Are MAIA insiders net buyers or net sellers?

Across the full Form 4 history for MAIA, 142 transactions (85%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MAIA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MAIA in?

MAIA Biotechnology, Inc. (MAIA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $77.03M.

MAIA insider trading

NYSE American Healthcare

MAIA Biotechnology, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

168

Last 90 days

Buys / sells

85% / 0%

Market cap

$77.03M

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Company website: maiabiotech.com

MAIA insider activity at a glance

FilingIQ has scored 168 insider transactions for MAIA since Jul 28, 2022. The most recent filing in our index is dated Apr 10, 2026.

Across the full history, 142 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MAIA insider trades is 47.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MAIA trades on FilingIQ Raw filings on SEC EDGAR

Latest MAIA Form 4 filings

Vitoc Vlad Chief Executive Officer

P Nov 28, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MAIA?: FilingIQ tracks 168 Form 4 insider transactions for MAIA (MAIA Biotechnology, Inc.), covering filings from Jul 28, 2022 onwards. 9 of those were filed in the last 90 days.
Are MAIA insiders net buyers or net sellers?: Across the full Form 4 history for MAIA, 142 transactions (85%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MAIA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MAIA in?: MAIA Biotechnology, Inc. (MAIA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $77.03M.

Methodology & sources

Every MAIA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.